CAMP4 THERAPEUTICS CORPORATION

Historical 13F Holders

Symbol
CAMP
CUSIP
13463J101
All holders as of
Q2 2026
Type
Equity
Class
COM
Reported Value, Excluding Options
Total Filings

13D/G Filers

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 13463J101 since 12/18/2024, newest first.

Filer % of Class Filed
5AM Ventures VI, L.P. 13D/A Amendment 3
9.9% 8/31/2026
Event 8/27/2026
Polaris Management Co. VII, L.L.C. 13D/A Amendment 2
6.3% 8/19/2026
Event 8/13/2026
Balyasny Asset Management L.P. 13G/A Amendment 1
4.99% 8/14/2026
Event 6/30/2026
Trails Edge Capital Partners, LP 13G
6.0% 8/10/2026
Event 8/3/2026
5AM Ventures VI, L.P. 13D/A Amendment 2
9.9% 8/5/2026
Event 8/3/2026
Balyasny Asset Management L.P. 13G
5.1% 5/15/2026
Event 3/31/2026
Enavate Sciences GP, LLC 13D/A Amendment 3
4.8% 3/11/2026
Event 3/9/2026
Vivo Opportunity Fund Holdings, L.P. 13G/A Amendment 1
7.4% 2/13/2026
Event 12/31/2025
FMR LLC 13G/A Amendment 2
9.5% 2/5/2026
Event 12/31/2025
Janus Henderson Group PLC 13G 12.2% 1/8/2026
Event 12/31/2025
Enavate Sciences GP, LLC 13D/A Amendment 2
6.0% 12/23/2025
Event 12/19/2025
Coastlands Capital LP 13G/A Amendment 1
10.0% 12/11/2025
Event 9/10/2025
Northpond Ventures II, LP 13G/A Amendment 1
4.8% 11/14/2025
Event 9/30/2025
AH Bio Fund I, L.P. 13G/A Amendment 1
4.5% 11/14/2025
Event 9/30/2025
FMR LLC 13G/A Amendment 1
6.7% 11/7/2025
Event 10/31/2025
FMR LLC 13G
15.0% 10/7/2025
Event 9/30/2025
HarbourVest Partners, LLC 13G/A Amendment 1
2.7% 10/1/2025
Event 9/30/2025
Vivo Opportunity Fund Holdings, L.P. 13G
7.6% 9/17/2025
Event 9/11/2025
Coastlands Capital LP 13G
10.0% 9/16/2025
Event 9/10/2025
Enavate Sciences GP, LLC 13D/A Amendment 1
8.1% 9/15/2025
Event 9/11/2025
5AM Ventures VI, L.P. 13D/A Amendment 1
12.5% 9/11/2025
Event 9/9/2025
Polaris Management Co. VII, L.L.C. 13D/A Amendment 1
8.4% 9/11/2025
Event 9/9/2025
HarbourVest Partners, LLC 13G
6.3% 5/14/2025
Event 12/31/2024

13F Holders by Quarter

Period Filings Shares, Excl. Options Value, Excl. Options
2026 Q3 1 241 $974.00
2026 Q2 62 41.7 M $182 M
2026 Q1 47 39.8 M $176 M
2025 Q4 40 38.2 M $235 M
2025 Q3 29 28.2 M $84.6 M
2025 Q2 31 11.7 M $17.0 M
2025 Q1 40 12.7 M $50.7 M
2024 Q4 37 12.9 M $67.1 M